DOTA-tris(acid)-amido-dPEG®₃-bromoacetamide (QBD-11150)

Description

DOTA-tris(acid)-amido-dPEG®3-bromoacetamide, product number QBD-11150, combines the macrocycle 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) through a single molecular weight, discrete polyethylene glycol (dPEG®) linker to a thiol-reactive bromoacetyl moiety that couples to the dPEG® linker via an amide bond. The linker contains 14 atoms and is 15.6 Å long from the terminal amide adjacent to the DOTA moiety to the methylene moiety adjacent to the bromine atom. This product is useful in radioimaging and radiotherapeutic applications.

DOTA is a highly popular bifunctional chelator used in a variety of diagnostic and therapeutic applications for the delivery of radionuclides, particularly lanthanide radionuclides and certain rare earth radioisotopes such as yttrium. For treatments using trivalent lanthanide radioisotopes, DOTA is the preferred ligand because it forms thermodynamically stable, kinetically inert complexes.
The bromoacetyl moiety (present as the bromoacetamide in QBD-11150) reacts chemoselectively, but not chemospecifically, with free thiol groups to form stable thioether bonds. The rate and selectivity of bromoacetyl for free thiols depend upon the pH of the reaction and the relative availability (compared to thiols) of other groups with which the bromoacetyl moiety can react (for example, surface-accessible primary amines).

The short, single molecular weight dPEG® linker between the DOTA and the bromoacetyl groups serves many purposes. It provides flexibility to the entire molecule. Because each ethylene glycol unit in the dPEG® chain hydrogen bonds up to three molecules of water, the molecule gains water solubility, and in aqueous environments such as blood, it increases the hydrodynamic volume of the molecule and of anything to which the molecule is conjugated. With larger hydrodynamic volume, conjugates are less susceptible to renal excretion, which means that lower doses of the diagnostic or therapeutic agent are needed for the conjugate to affect its purpose. Moreover, dPEG® is non-immunogenic, and its large hydrodynamic volume helps reduce the immunogenicity of molecules to which it is conjugated.

Specifications

Documents

References

Greg T. Hermanson, Bioconjugate Techniques, 2nd Edition, Elsevier Inc., Burlington, MA 01803, April, 2008 (ISBN-13: 978-0-12-370501-3; ISBN-10: 0-12-370501-0). Specifically see pp. 726-729 in his Chapter 18 on discrete PEG compounds for pegylation applications.

Greg T. Hermanson, Bioconjugate Techniques, 3rd Edition, Elsevier, Waltham, MA 02451, 2013, ISBN 978-0-12-382239-0; See chapter 18, Discrete PEG Reagents, pp.787-821, for a full overview of the dPEG® products.